اتصل بنا
عن الشركة
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass. It was founded in 1998 and is based in Uniondale, New York.
US
مجهول
لم يتم التحقق من الشركة
شفافية الأعمال
- لم يتم التحقق من معلومات الشركة
- اطلب من عملائهم آراءهم
- لم يرد على المراجعات السلبية